8-K
filed May 12, 2026, 4:07 PM ET
ticker OPRX
CIK 0001448431
earnings
confidence high
sentiment neutral
materiality 0.50
OptimizeRx Corp (OPRX): debt financing — OptimizeRx Q1 rev $19.8M, adj EBITDA $3.3M; guides FY rev $95-100M, refi saves $1.5M
OptimizeRx Corp
- Q1 revenue $19.8M (down 10% YoY), GAAP net loss $(0.5)M ($(0.03)/share) vs $(2.2)M loss a year ago.
- Non-GAAP net income $2.7M ($0.14/diluted), adjusted EBITDA $3.3M vs $1.5M prior year.
- FY 2026 revenue guidance updated to $95-100M; adjusted EBITDA guidance unchanged $21-25M.
- Refinanced debt with Fifth Third Bank: $25M term loan + $10M revolver, annual interest savings ~$1.5M.
- Launched efficiency initiatives expected to save $3M annually, including $1M in 2026.
Key facts
Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
OptimizeRx Corp incurred credit facility of $35.0 million with Fifth Third Bank, National Association at Base Rate or Term SOFR plus an applicable margin ranging from 0.75% to 1.50% for maturing May 7, 2031.
- Instrument
- credit facility
- Principal
- $35.0 million
- Counterparty
- Fifth Third Bank, National Association
- Rate
- Base Rate or Term SOFR plus an applicable margin ranging from 0.75% to 1.50% for
- Maturity
- May 7, 2031
- Event
- incurrence
Exact text from the filing
Lead Arranger and Sole Bookrunner in connection with the Credit Agreement. The Credit Agreement provides for senior secured credit facilities in an aggregate principal amount of $35.0 million on the Closing Date, consisting of (i) a $10.0 million revolving credit facility (the “Revolving Facility”), which includes a $250,000 letter of credit subfacility and a swing
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 0.95
OptimizeRx Corp reported first quarter ended March 31, 2026 results: revenue $19.8 million, net income $(0.5) million, EPS $(0.03) per share. Guidance reaffirmed.
- Period
- first quarter ended March 31, 2026
- Revenue
- $19.8 million
- Net income
- $(0.5) million
- EPS
- $(0.03) per share
- Guidance
- reaffirmed
- Result
- reported results
Exact text from the filing
specific reference in such filing. --- EX-99.1 (EX-99.1) --- OptimizeRx Reports First Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance - Q1 revenue totals $19.8 million - Q1 net loss and adjusted EBITDA came in at $(0.5) million and $3.3 million, respectively - 2026 revenue guidance updated to $95-$100 million; adjusted EBITDA guidance unchanged
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OptimizeRx Corp terminated Existing Term Loan with Blue Torch Finance, LLC (effective 2026-05-07).
- Action
- termination
- Agreement
- credit facility
- Counterparty
- Blue Torch Finance, LLC
- Effective
- 2026-05-07
Exact text from the filing
On the Closing Date, the Company terminated and repaid in full all obligations outstanding under the Existing Term Loan with the proceeds from the new Term Loan.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
OptimizeRx Corp entered into Credit Agreement with Fifth Third Bank, National Association valued at $35.0 million (effective 2026-05-07).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- Fifth Third Bank, National Association
- Value
- $35.0 million
- Effective
- 2026-05-07
Exact text from the filing
On May 7, 2026 (the “Closing Date”), OptimizeRx Corporation, a Nevada corporation (the “Company” or “Borrower”), entered into a credit agreement (the “Credit Agreement”) with the other loan parties from time to time party thereto (the “Loan Parties”), the lenders from time to time party thereto (the “Lenders”), and Fifth Third Bank, National Association (“Fifth Third”), as Agent, L/C Issuer and Swing Line Lender.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.